ba0001pp145 | Cancer and bone: basic, translational and clinical | ECTS2013
Gobel Andy
, Thiele Stefanie
, Rauner Martina
, Lorenz C Hofbauer
, Tilman D Rachner
Introduction: Bone metastases represent a frequent complication of breast cancer and are characterized by increased tumour-driven activation of osteoclasts and subsequent bone loss. Aminobisphosphonates inhibit osteoclast function and are established therapies of skeletal metastases. Similar to statins, they block the mevalonate pathway and are thought to have direct anti-tumour effects. Here, we report on the anti-tumour potential of a sequential inhibition of the mevalonate ...